Press Releases

Print Page   Print Page       E-mail Page   Email Page       RSS Feeds   RSS       E-mail Alerts  Email Alerts       Financial Tear Sheet  Tear Sheet

Press Releases

Date Title
10/07/19 Alkermes Presents New Health Economics and Outcomes Research on Patients With Schizophrenia and Bipolar I Disorder at 2019 Psych Congress
09/26/19 Alkermes to Present at the Cantor Fitzgerald Global Healthcare Conference
09/13/19 Alkermes Announces the Appointment of Richard Gaynor, M.D. and Andy Wilson to its Board of Directors and the Retirement of Director Floyd Bloom, M.D.
07/30/19 Diroximel Fumarate Demonstrated Significantly Improved Gastrointestinal Tolerability Profile Compared to Dimethyl Fumarate in Patients with Multiple Sclerosis
07/29/19 Alkermes Announces Settlement With Amneal Over VIVITROL® Patent Dispute
07/25/19 Alkermes Plc Reports Second Quarter 2019 Financial Results
07/18/19 Alkermes to Host Conference Call to Discuss Second Quarter 2019 Financial Results
07/15/19 Alkermes Expands Planned New Drug Application for ALKS 3831 to Include Treatment of Bipolar I Disorder
07/01/19 Alkermes Demonstrates Commitment to Local Community for 11th Consecutive Year With Largest Volunteer Event in Company History
06/12/19 Alkermes Advances ALKS 4230 into Monotherapy Expansion Phase of ARTISTRY-1 in Patients With Renal Cell Carcinoma or Melanoma
05/22/19 Alkermes to Present New Data From Mental Health Portfolio at the American Society of Clinical Psychopharmacology 2019 Annual Meeting
05/14/19 Alkermes to Present at the UBS Global Healthcare Conference
05/13/19 Alkermes to Showcase Leadership in Schizophrenia With New Data Presentations at Upcoming Scientific Conferences
04/25/19 Alkermes Plc Reports First Quarter 2019 Financial Results
04/24/19 Alkermes Appoints Industry Veteran C. Todd Nichols as Senior Vice President of Sales and Marketing
Displaying 61 - 75 of 795